During this period, the biology of the disease may have changed owing to hormonal changes arising from obesity, the use of hormone replacement therapy, and reproductive factors.17 New systemic therapies, including aromatase inhibitors and taxanes, have become established in clinical use,18 and surgery and radiotherapy have become better targeted. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.